Selectivity for TP53 signalling drives the mode of action of a highly potent N,O,O-tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate

Journal:
Chemical Science
Published:
DOI:
10.1039/d5sc00735f
Affiliations:
6
Authors:
19
Go to article
Institutions Authors Share
University of Vienna, Austria
10.500000
10.500000
 0.55
Comprehensive Cancer Center Vienna (CCC), Austria
3.333333
 0.18
Research Platform Translational Cancer Therapy Research, Austria
3.333333
 0.18
Joint Metabolome Facility (JMEF), Austria
1.833333
 0.10
Interested in Oncology and Carcinogenesis?